Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478826 · ClinicalTrials.gov registry record
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
A clinical trial of Interstitial Lung Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 635
- Enrollment target
- 1
- Study location
NCT03478826: Recruiting study of Interstitial Lung Disease, sponsored by Mayo Clinic.
NCT03478826 is a study of Interstitial Lung Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 635 participants, above the 549-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (16% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03478826, a study of Interstitial Lung Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 635 participants
- Enrollment target
- 1
- Study location
Study Summary
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Primary Outcome
Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease.
Conditions Studied
Interventions
- OTHER ILD
- OTHER Healthy
- OTHER Pneumonia
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 635 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2028-01 |
What NCT03478826 shows while recruiting
NCT03478826 is an observational study that tracks outcomes without assigning an intervention. The registered 635 participants enrollment target is mid-sized for trials with a published cap, above the 549-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (16% higher).
The record links to 1 condition, with Interstitial Lung Disease appearing as the primary indexed condition, and to 3 interventions - of which ILD is the first listed.
NCT03478826 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03478826 about?
NCT03478826 is a clinical study titled "Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)". To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
What is the current status of trial NCT03478826?
This trial is currently recruiting. The enrollment target is 635 participants. The study started on 2018-08-01. Estimated completion is 2028-01.
What conditions does trial NCT03478826 study?
This clinical trial studies the following conditions: Interstitial Lung Disease.
What interventions are being tested in trial NCT03478826?
The interventions under investigation include: ILD (OTHER), Healthy (OTHER), Pneumonia (OTHER).
Who is sponsoring clinical trial NCT03478826?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478826 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03478826's enrollment target sits among peer trials
635 7th of 36 higher than 30 of 36 other Interstitial Lung Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Lung Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RECRUITING · Phase 3
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821129 · 636 participants · NA
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
- NCT07237295 · 634 participants · NA
CommunityRx-Kidney Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI